Related references
Note: Only part of the references are listed.Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study
Franziska Erlmeier et al.
CLINICAL GENITOURINARY CANCER (2021)
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
Horst-Dieter Hummel et al.
IMMUNOTHERAPY (2021)
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
Kiril Trpkov et al.
MODERN PATHOLOGY (2021)
High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma
Iris Polifka et al.
HUMAN PATHOLOGY (2019)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2019)
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Yazhuo Zhang et al.
MOLECULAR CANCER (2018)
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
Matthew T. Campbell et al.
EUROPEAN JOURNAL OF CANCER (2018)
c-Met in chromophobe renal cell carcinoma
Franziska Erlmeier et al.
MEDICAL ONCOLOGY (2017)
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
Sean Caenepeel et al.
Oncotarget (2017)
Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma
Julia Bellut et al.
SCIENTIFIC REPORTS (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer
Phillip Mikah et al.
BMC CANCER (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
Cabozantinib for the treatment of renal cell carcinoma
Bernard Escudier et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
W. Marston Linehan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Liem M. Phan et al.
CANCER RESEARCH (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic Impact of Major Receptor Tyrosine Kinase Expression in Gastric Cancer
Yukinori Kurokawa et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma
Ildiko Mesteri et al.
EUROPEAN JOURNAL OF CANCER (2014)
Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer
Matthias Preusser et al.
HISTOPATHOLOGY (2014)
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
G. T. Gibney et al.
ANNALS OF ONCOLOGY (2013)
Prognostic Factors of Papillary Renal Cell Carcinoma: Results From a Multi-Institutional Series After Pathological Review
Edwin Herrmann et al.
JOURNAL OF UROLOGY (2010)
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells
Alyssa R. Bonine-Summers et al.
CANCER BIOLOGY & THERAPY (2007)
Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma
Yasuyoshi Miyata et al.
CLINICAL CANCER RESEARCH (2006)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Biological significance of c-met over expression in papillary renal cell carcinoma
P Sweeney et al.
JOURNAL OF UROLOGY (2002)
Share Paper
